Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Rifkin

Cardiovascular Disease Saint Louis, MO Medical Doctor

NPI 1417975053 CMS profile 290657

4921 Parkview Pl Ste 8A, Ste 8A, Saint Louis, MO 63110

Open in the dashboard

General payments

$144,531

101 records reported · program years 2019–2025

Research payments

$135,012

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Rifkin of Saint Louis, MO is reported in the CMS Open Payments database as having received $144,531 across 101 general payments and $135,012 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $310 15
2025 Research $612 1
2024 General $407 19
2024 Research $134,400 1
2023 General $97,422 36
2022 General $28,336 13
2021 General $17,902 13
2020 General $100 1
2019 General $53 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Rifkin
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Robert Rifkin were reported at $310. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Robert Rifkin Cardiovascular Disease median Middle half National median
2019 $53 $450 $127–$1,392 $163
2020 $100 $242 $77–$751 $114
2021 $17,902 $335 $101–$1,037 $132
2022 $28,336 $395 $121–$1,211 $149
2023 $97,422 $443 $136–$1,283 $160
2024 $407 $450 $136–$1,323 $164
2025 $310 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $142,340 46 payments
  2. Amgen Inc. $974 1 payment
  3. Lundbeck LLC $330 14 payments
  4. Almatica Pharma LLC $136 9 payments
  5. LivaNova USA, Inc. $130 5 payments
  6. Dentsply Sirona Inc $100 1 payment
  7. NeuroPace, Inc. $95 1 payment
  8. Ironshore Pharmaceuticals Inc. $89 4 payments
  9. Axsome Therapeutics, Inc. $66 3 payments
  10. Bausch Health US, LLC $63 3 payments
  11. Other $207 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $78,624 12 payments
  2. Consulting Fee $64,690 35 payments
  3. Food and Beverage $1,117 53 payments
  4. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. REXULTI Psychiatry $330 14 payments
  2. LOREEV XR $136 9 payments
  3. CEREC $100 1 payment
  4. VNS THERAPY SYMMETRY MODEL 8103 GENERATOR $99 3 payments
  5. RNS Neurostimulator Kit $95 1 payment
  6. JORNAY PM $89 4 payments
  7. Auvelity $66 3 payments
  8. APLENZIN $43 2 payments
  9. Adzenys XR-ODT $42 3 payments
  10. REXULTI Psychiatry $36 2 payments
  11. Other $245 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $134,400 1 payment
  2. Boehringer Ingelheim International GmbH $612 1 payment

Records

103 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record